Item 8.01 Other Events.
On June 3, 2023, Cyteir Therapeutics, Inc. issued a press release titled
"CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and
Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic
Malignancies". A copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release of Cyteir Therapeutics, Inc. dated June 3, 2023
104 Cover Page Interactive Data File (embedded within the inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses